Patent Application: Multispecific Binding Constructs Against Checkpoint Molecules

ChangeBridge: Patent Apps - Peptides (C07K)

Published November 24th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a new patent application (US20260085121A1) from Compass Therapeutics, LLC, detailing multispecific binding constructs against checkpoint molecules. The application focuses on compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression, specifically blocking interactions between PD-1 and its ligand.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260085121A1) filed by Compass Therapeutics, LLC, on November 24, 2025. The application describes "Multispecific Binding Constructs Against Checkpoint Molecules and Uses Thereof," focusing on compositions and methods to inhibit tumor evasion by reducing immune checkpoint suppression. Specifically, it details blocking the interaction between PD-1 and its ligand (PD-L1/PD-L2) while promoting cell interaction.

This patent application does not impose immediate regulatory obligations on companies. However, it is relevant for pharmaceutical and biotechnology companies involved in oncology drug development, particularly those working with immune checkpoint inhibitors. Compliance officers in these sectors should be aware of this filing as it pertains to intellectual property in the field of cancer therapeutics and may impact future research and development strategies.

Source document (simplified)

← USPTO Patent Applications

MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF

Application US20260085121A1 Kind: A1 Mar 26, 2026

Assignee

Compass Therapeutics, LLC

Inventors

Bing GONG, Rachel RENNARD, Amanda Frank OLIPHANT, Cheuk Lun LEUNG, Benjamin Jacob WOLF, Ugur ESKIOCAK, Pearl BAKHRU, Diana I. ALBU

Abstract

The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.